September 14, 2021
Sponsored by Eurofins Biopharma
Industry changes, such as shorter timelines and increased product complexity, can often introduce additional risks to the sterile fill/finish process, resulting in production delays, additional costs, and safety concerns. Additionally, the advent of personalized medicines brings challenges to manufacturing and supply chain structure, emphasizing the need for speed and flexibility.
Join Eurofins BioPharma Product Testing and Vanrx (now part of Cytiva), for an in-depth discussion covering ways to eliminate human error and other associated risks when producing small batches of sterile GMP product for Phase 1 and 2 clinical trials. Learn how we can help increase speed and flexibility to drive your drug product into the clinic, and ultimately to patients faster with:
In-process capabilities for sterile fill/finish manufacturing
An overview of large and small molecule product types supported, including cell and gene therapy products, personalized medicines, and more
An in-depth look at the design specifications of the Vanrx Microcell Vial Filler and the benefits of using a closed robotic system for aseptic filling
A comprehensive overview of the specifications supported, such as batch sizes, vial types and container closures, options for sterile filtrations, labeling, kitting, distribution and logistics, and more
Click here to register for this on-demand webinar.
You May Also Like
